• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dow Drops Over 300 Points After Fed Raises Key Overnight Interest Rate By 50 bps

    12/14/22 2:37:14 PM ET
    $DS
    $ICVX
    $IMMX
    $KSPN
    Real Estate Investment Trusts
    Real Estate
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DS alert in real time by email

    U.S. stocks turned lower toward the end of trading, after the Federal Reserve announced its policy decision.

    The Dow traded down 0.99% to 33,771.65 while the NASDAQ fell 1.52% to 11,085.67. The S&P 500 also fell, dropping, 1.12% to 3,974.57.

    Also check this: Bitcoin Tops $18,000; GMX, Dogecoin Among Top Losers


    Leading and Lagging Sectors


    Health care shares rose by 0.2% on Wednesday. Meanwhile, top gainers in the sector included Avidity Biosciences, Inc. (NASDAQ:RNA), up 62%, and Icosavax, Inc. (NASDAQ:ICVX), up 61%.


    In trading on Wednesday, materials shares fell by 1%.


    Top Headline

     

    The Federal Reserve raised its target fed funds rate by 0.5% on Wednesday to a new range of between 4.25% and 4.5%.

    The Fed said it will continue with its previously announced plan to let Treasury securities and agency debt and agency mortgage-backed securities roll off its balance sheet on a monthly basis.

     

    Equities Trading UP

     

    • Avidity Biosciences, Inc. (NASDAQ: RNA) shares shot up 59% to $17.47 after the company announced AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA trial demonstrating the first-ever successful targeted delivery of RNA into muscle.
    • Shares of Vallon Pharmaceuticals, Inc. (NASDAQ:VLON) got a boost, shooting 92% to $0.4828 after the company entered into a definitive merger agreement with GRI Bio.
    • Immix Biopharma, Inc. (NASDAQ:IMMX) shares were also up, gaining 31% to $1.9392 after the company announced it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% ORR and 71% CR/sCR at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial.

     

    Equities Trading DOWN

    • Netcapital Inc. (NASDAQ:NCPL) shares tumbled 36% to $1.41 after the company announced pricing of a public offering.
    • Shares of Drive Shack Inc. (NYSE:DS) were down 57% to $0.2038. The company announced its intention to voluntarily delist from the NYSE and to deregister its common stock.
    • Kaspien Holdings Inc. (NASDAQ:KSPN) was down, falling 24% to $0.7480 after the company reported a wider Q3 loss.


    Also check out: Markets Turn More Bullish Following Inflation Data


    Commodities

    In commodity news, oil traded up 2.7% to $77.40 while gold traded down 0.3% at $1,820.30.


    Silver traded up 0.5% to $24.10 on Wednesday while copper rose 1% to $3.8790.


    Stocks of crude oil in the US increased by 7.819 million barrels in the week ended December 9, versus a 6.426 million-barrels decline in the prior week, the American Petroleum Institute said. The EIA, on Wednesday, said stocks of crude oil in the US rose by 10.23 million in the week ended December 9, recording the first rise in five weeks.

     


    Euro zone


    European shares were mostly lower today. The eurozone’s STOXX 600 fell 0.02%, London’s FTSE 100 fell 0.09% while Spain’s IBEX 35 Index gained 0.4%. The German DAX dropped 0.26%, French CAC 40 fell 0.21% and Italy’s FTSE MIB Index slipped 0.26%.


    Industrial production in the Eurozone dropped 2.0% from a month ago in September, following a revised 0.8% increase in September. Spain's consumer price inflation declined to 6.8% year-over-year in November, compared to July's 38-year high level of 10.8%. The annual inflation rate in the UK fell to 10.7% in November from 11.1% a month ago.

     


    Asia Pacific Markets


    Asian markets closed mostly higher on Wednesday, with the Japan’s Nikkei gaining 0.72% and Hong Kong’s Hang Seng Index rising 0.39%. China’s Shanghai Composite Index rose 0.01%.


    The annual wholesale price inflation rate in India eased to 5.85% in November from 8.39% in the previous month. Industrial production in Japan dropped by 3.2% month-over-month in October following a final 1.7% decline a month ago. Japan's core machinery orders rose 5.4% month-over-month in October

     

    Economics

     

    • US import prices fell 0.6% from a month ago in November versus a revised 0.4% drop in the prior month. Export prices declined by 0.3% from a month earlier.
    • The Fed raised its key overnight interest rate by 50 bps.


    Check out this: Market Volatility Drops Sharply Ahead Of Fed's Rate Decision


    COVID-19 Update

    The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 101,419,850 cases with around 1,110,560 deaths. India confirmed a total of at least 44,676,360 cases and 530,650 deaths, while France reported over 38,612,750 COVID-19 cases with 169,000 deaths. In total, there were at least 655,097,450 cases of COVID-19 worldwide with more than 6,662,410 deaths.

    Get the next $DS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DS
    $ICVX
    $IMMX
    $KSPN

    CompanyDatePrice TargetRatingAnalyst
    Immix Biopharma Inc.
    $IMMX
    3/25/2026$20.00Overweight
    Morgan Stanley
    Atrium Therapeutics Inc.
    $RNA
    3/11/2026$25.00Overweight
    Wells Fargo
    Immix Biopharma Inc.
    $IMMX
    3/9/2026$23.00Mkt Outperform
    Citizens
    Immix Biopharma Inc.
    $IMMX
    2/9/2026$14.00Outperform
    Mizuho
    Atrium Therapeutics Inc.
    $RNA
    9/17/2025$62.00Buy
    Roth Capital
    Atrium Therapeutics Inc.
    $RNA
    7/10/2025$55.00Buy
    Goldman
    Atrium Therapeutics Inc.
    $RNA
    6/24/2025$50.00Outperform
    Bernstein
    Atrium Therapeutics Inc.
    $RNA
    6/17/2025$55.00Outperform
    Wolfe Research
    More analyst ratings

    $DS
    $ICVX
    $IMMX
    $KSPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Expands Strategy to Build Full-Service Capital Markets Infrastructure for Growth Companies

    Boston, MA, April 22, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) ("Netcapital" or the "Company"), a publicly traded fintech company that gives companies access to capital markets infrastructure without institutional scale fees, today announced its strategic focus on enhancing the Netcapital platform into a more full-service capital formation solution for emerging growth companies. Under the leadership of Chief Executive Officer Todd Violette, Netcapital plans to build on its existing SEC-registered funding portal and FINRA member broker-dealer capabilities by expanding the services and tools that support issuers throughout the capital raising process. The goal is to pr

    4/22/26 8:30:00 AM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company. The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of t

    4/20/26 10:46:00 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DS
    $ICVX
    $IMMX
    $KSPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Rachman Ilya M bought $4,976 worth of shares (746 units at $6.67), increasing direct ownership by 0.07% to 1,141,683 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:49:30 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CFO Morris Gabriel S exercised 156,000 in-the-money shares at a strike of $0.80 and bought $5,067 worth of shares (770 units at $6.58), increasing direct ownership by 0.26% to 291,429 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    12/10/25 6:47:20 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO and Chairman Rachman Ilya M bought $5,050 worth of shares (2,500 units at $2.02), increasing direct ownership by 0.22% to 1,140,937 units (SEC Form 4)

    4 - Immix Biopharma, Inc. (0001873835) (Issuer)

    9/17/25 5:20:33 PM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DS
    $ICVX
    $IMMX
    $KSPN
    SEC Filings

    View All

    SEC Form S-8 filed by Atrium Therapeutics Inc.

    S-8 - Atrium Therapeutics, Inc. (0002093101) (Filer)

    4/17/26 4:05:34 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Netcapital Inc. (0001414767) (Filer)

    4/16/26 4:15:17 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    SEC Form 424B3 filed by Netcapital Inc.

    424B3 - Netcapital Inc. (0001414767) (Filer)

    4/14/26 6:19:48 AM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $DS
    $ICVX
    $IMMX
    $KSPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley initiated coverage on Immix Biopharma with a new price target

    Morgan Stanley initiated coverage of Immix Biopharma with a rating of Overweight and set a new price target of $20.00

    3/25/26 8:30:25 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Atrium Therapeutics with a new price target

    Wells Fargo initiated coverage of Atrium Therapeutics with a rating of Overweight and set a new price target of $25.00

    3/11/26 8:36:38 AM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Immix Biopharma with a new price target

    Citizens initiated coverage of Immix Biopharma with a rating of Mkt Outperform and set a new price target of $23.00

    3/9/26 9:07:22 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DS
    $ICVX
    $IMMX
    $KSPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Kenney Stephanie

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:12 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hughes Steven George

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:54:06 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Winslow Brendan R.

    4 - Atrium Therapeutics, Inc. (0002093101) (Issuer)

    4/22/26 5:53:36 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DS
    $ICVX
    $IMMX
    $KSPN
    Leadership Updates

    Live Leadership Updates

    View All

    Netcapital Appoints Todd Violette as Chief Executive Officer

    BOSTON, MA, April 16, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a publicly traded fintech company that gives companies access to capital markets infrastructure without institutional-scale fees, today announced that its Board of Directors has appointed Mr. Violette to lead the Company in order to accelerate capital formation, expand platform reach, and build long-term shareholder value. Mr. Violette brings over 25 years of leadership experience across capital markets, fintech and digital asset-related businesses. His recent operating and executive roles have included CEO of CloudCover International, CEO of AppYea Inc., CEO of Vinergy, Chief Investment

    4/16/26 4:05:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Netcapital Inc. Announces Appointment of Rich Wheeless as CEO

    NCPL to Expand Beyond Traditional Securities into Crypto and Blockchain-Enabled Investments BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)) (the "Company"), a digital private capital markets ecosystem, today announced the appointment of Rich Wheeless as CEO. Former CEO, Martin Kay, will remain as an advisor to the company. Mr. Wheeless is a seasoned executive with more than 20 years of financial leadership and corporate management experience across multiple industries in both public and private enterprises. He was most recently the Chief Executive Officer of a publicly traded logistics and warehousing solutions company and has served as an active inves

    12/8/25 5:00:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

    – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

    10/29/24 8:00:00 AM ET
    $AMAM
    $KURA
    $RNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $DS
    $ICVX
    $IMMX
    $KSPN
    Financials

    Live finance-specific insights

    View All

    Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration

    SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv

    4/23/26 8:00:00 AM ET
    $BMY
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Netcapital Reports Third Quarter Fiscal 2026 Financial Results and Provides Corporate Update

    Key milestones include acquisition of Iverson Design and signing PureWave Hydrogen as first tokenization clientManagement to host business update conference call tomorrow at 10:00 am ET BOSTON, MA, March 19, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW, Netcapital)) (the "Company"), a digital private capital markets ecosystem, today announced financial results and provided corporate highlights for the third quarter of fiscal 2026 ended January 31, 2026. In addition, management plans to host a business update conference call tomorrow, March 20, 2026, at 10:00 a.m. ET. "We completed several key transactions in fiscal Q3 2026," said Rich Wheeless, Netcapital's Chief Executiv

    3/19/26 5:57:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Netcapital Acquires Iverson Design Assets and Proprietary AI Design Technology Suite

    Accelerates Transformation into Tokenization and Digital Asset Platform BOSTON, MA, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Netcapital Inc. (NASDAQ:NCPL, NCPLW)), a digital private capital markets ecosystem, today announced the acquisition of the assets of Iverson Design, LLC, a creative studio and developer of AI-powered design and visualization tools. Led by multimedia and AI designer Michael Iverson, the studio develops motion graphics, 3D product visualization, investor presentations, and immersive digital experiences. As part of the transaction, Michael Iverson joins Netcapital as Chief Design Director and Head of AI Experience. Under the agreement, Netcapital acquired Iverson Design's f

    1/6/26 4:22:00 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $DS
    $ICVX
    $IMMX
    $KSPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 7:25:20 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    Amendment: SEC Form SC 13G/A filed by Avidity Biosciences Inc.

    SC 13G/A - Avidity Biosciences, Inc. (0001599901) (Subject)

    11/14/24 5:46:11 PM ET
    $RNA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Netcapital Inc.

    SC 13G/A - Netcapital Inc. (0001414767) (Subject)

    11/14/24 4:23:19 PM ET
    $NCPL
    Finance: Consumer Services
    Finance

    $DS
    $ICVX
    $IMMX
    $KSPN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Immix Biopharma Inc. on Jun 5

    Recent insider purchases at Immix Biopharma Inc. have caught the attention of investors, with Morris Gabriel S leading the way by acquiring $5,973 worth of shares on June 5, 2024. This transaction involved 3,300 units at a price of $1.81 per share, increasing Gabriel's direct ownership by 1% to 283,334 units, as reported in SEC Form 4. This move indicates Gabriel's confidence in the company's potential and may be seen as a positive signal by market participants. Click here for more details. Looking back at previous insider transactions, we can identify a few interesting patterns. On May 15, 2024, Rachman Ilya M purchased $9,660 worth of shares, comprising 4,300 units at $2.25 per share, whi

    6/10/24 1:09:24 AM ET
    $IMMX
    Biotechnology: Pharmaceutical Preparations
    Health Care